These findings remain investigational
The European Medicines Agencys (EMA) Pharmacovigilance Risk Assessment Committee concluded that no product label update was warranted, based on data from clinical trials, real-world safety monitoring, and electronic health records [45]
24.Rosenstock J, Frias J, Jastreboff AM, et al
More serious risks include: Pancreatitis Gallbladder issues Risk of thyroid tumors (observed in rodent studies) Patients must weigh these risks carefully, especially when using the medication off-label
A large, population-based retrospective cohort study was conducted using the TriNetX platform, which provided real-time access to electronic health records of 634,265 adult patients with MASLD/MASH
Some patients report needing longer to achieve the same appetite suppression when restarting after a break